Drugs /

rad140

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable, non-steroidal selective androgen receptor modulator (SARM), with potential tissue-selective androgenic/anti-androgenic activities. Upon oral administration, vosilasarm acts as an agonist in select tissues, such as skeletal muscle and bone, where it binds to and activates androgen receptors (ARs). In the prostate and breasts, RAD140 acts as an antagonist and blocks AR activation and AR-mediated cellular proliferation. Therefore, this agent may improve bone formation and muscle mass and strength, and may inhi

Clinical Trials

View Clinical Trials for rad140

Rad140 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating rad140, 1 is phase 1 (0 open).

ER Expression, ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for rad140 clinical trials.

Breast carcinoma is the most common disease being investigated in rad140 clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Rad140
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating rad140 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
vosilasarm, testolone, sarm rad140, selective androgen receptor modulator rad140
NCIT ID [1]:
C137950

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.